Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2019 | DIRVA: intratumorally injected durvalumab for cervical cancer

Gemma Kenter • 2 Jun 2019
ASCO 2019
Cervical Cancer Gynecological Cancer Durvalumab
DIRVA

Gemma Kenter, MD, PhD, of the Amsterdam Centre for Oncological Gynaecology, Amsterdam, The Netherlands, tells about the DIRVA trial which investigated intratumorally injected durvalumab for the treatment of cervical cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Gemma Kenter

1:59
Cervical cancer: does the western world have a benefit?
Gemma Kenter • 2 Jun 2019
2:03
HPV vaccinations
Gemma Kenter • 2 Jun 2019

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals